Impact of Severe COVID-19 on Accelerating Dementia Onset: Clinical and Epidemiological Insights

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: March 27, 2025

Severe COVID-19 infection has been associated with neurological complications, but its role in accelerating cognitive decline remains unclear. To determine whether individuals hospitalized for severe exhibit a higher incidence of new onset impairment compared to those other conditions. A retrospective study emulating target trial using Mass General Brigham electronic health records (March 2020-August 2024). The causal effect hospitalization was estimated via cumulative functions accounting the competing risk death. Multicenter hospital-based across healthcare system. total 221613 patients met eligibility criteria, including 6454 (2.0%) admitted due and 215159 (98.0%) all Patients were excluded if they had less than three months follow-up (due censoring, impairment, or death), younger 55 years at baseline, no prior visit year before baseline. primary outcome new-onset identified ICD codes dementia medication prescriptions. analysis hazard ratio relative hospitalizations, along difference 4.5 functions. Inverse propensity score weighting used balance covariates (age, sex, comorbidities, period). Among eligible (mean [SD] age, 69.55 [9.42] years, 55% female), significantly older more comorbidities (p < 0.05). developing (Hazard Ratio: 1.14 [95% CI: 1.02-1.30], P = 0.018). At 12.5% 11.3-13.5] group, 11.6% 11.1-12.1] non-COVID-19 group. an elevated clinically recognized impairment. Future studies are needed validate findings care settings. Early screening intervention may help optimize long-term outcomes patients. Question: Do have conditions?Findings: In this patients, COVID-19, observed among patients.Meaning: recognition diagnosis crucial optimizing patient outcomes.

Language: Английский

Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 22, 2024

Abstract Background and objectives New onset persistent headache has been reported following acute COVID-19 to some degree also after SARS-CoV-2 vaccination. The mechanisms for these types are unclear. purpose of this study was assess levels amyloid related biomarkers in patients with vaccine. Methods In prospective observational cohort, severe as the dominating symptom (n=29) vaccination (n=31), had neurological assessments reassessments 6 months. Plasma precursor protein (APP), pregnancy zone (PZP), cathepsin L1 (CTSL) serum Amyloid A (SAA1) were measured by ELISA relation healthy controls (n=16). Results We found a strong upregulation APP compared two other groups. At both inclusion months increased those accompanying cognitive symptoms. contrast, plasma PZP elevated at controls. CTSL only associated vaccine baseline, whereas SAA1 showed comparable all Conclusion Altered soluble markers potentially reflecting changes processing particular where we association NCT04576351 NCT05235776 What is already known on topic occurs subset individuals extent However, pathophysiological unknown. adds that could reflect How might affect research, practice or policy Our data underscore need more long-time follow-up new include blood tests neuroinflammation.

Language: Английский